Jupiter Neurosciences, INC 8-K filings

Jupiter Neurosciences, Inc. has filed a Form 8-K to announce a 1-for-75 reverse stock split, effective August 6, 2026, aimed at increasing its stock price to comply with Nasdaq listing rules.

Jupiter Neurosciences, Inc. disclosed the issuance and sale of 11,470,000 shares of Common Stock to YA II PN, Ltd. for approximately $3.6 million.

Jupiter Neurosciences, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors, ratification of auditors, and approval of equity plan and reverse stock split amendments.

Jupiter Neurosciences has secured an exclusive U.S. license for PharmAla's ALA-002, a psychedelic compound for neuroinflammation, involving significant upfront and milestone payments.

Jupiter Neurosciences, Inc. announced the appointment of Dr. Tomas J. Philipson, a health care economist, to its Board of Directors, effective June 26, 2026.

Jupiter Neurosciences, Inc. has updated executive employment terms and issued stock option grants to key leadership and directors.

Jupiter Neurosciences announced the pricing of a registered direct offering expected to raise approximately $2.0 million.

Jupiter Neurosciences has entered into a term sheet to acquire exclusive U.S. rights to PharmAla Biotech's ALA-002, a next-generation MDMA therapeutic.

Jupiter Neurosciences, Inc. received notices from Nasdaq regarding non-compliance with minimum bid price and market value of listed securities requirements, risking delisting.

Jupiter Neurosciences, Inc. announced the consummation of its second pre-paid advance closing, securing $1.86 million from YA II PN, LTD under its Standby Equity Purchase Agreement.

Jupiter Neurosciences' stockholders approved a significant increase in authorized shares and a new equity incentive plan, alongside re-electing its board and ratifying its auditor.

Jupiter Neurosciences, Inc. filed an amendment to its Standby Equity Purchase Agreement and Convertible Promissory Note with YA II PN, Ltd., adjusting share counts and conversion caps.

Jupiter Neurosciences, Inc. has entered into agreements with Yorkville Advisors Global, LP for up to $20 million in financing to fund its Parkinson's trial and Nugevia product line.

Jupiter Neurosciences, Inc. announced it has successfully regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing on the exchange.

Jupiter Neurosciences, Inc. has approved a bonus package for its executive officers, comprising stock options and cash payments, in recognition of their contributions to the company's successful December 2024 initial public offering and their financial concessions in 2024.

Jupiter Neurosciences replaces Assurance Dimensions, LLC with Cherry Bekaert LLP as its independent registered public accounting firm, effective April 16, 2025, following AD's decision to discontinue its PCAOB registrants practice.

Jupiter Neurosciences receives notification from Nasdaq for failing to meet the minimum bid price requirement of $1.00 per share.

Jupiter Neurosciences has agreed to a $20,000 monthly fee for financial services from Titan Advisory Services for 2025, with potential for bonuses and equity compensation.

Jupiter Neurosciences has entered into a strategic agreement with Dominant Treasure Health Company Limited to facilitate product development and distribution in Southeast Asia.

Jupiter Neurosciences successfully closed its initial public offering, raising $11 million and commencing trading on the Nasdaq Capital Market under the ticker symbol JUNS.

Jupiter Neurosciences has amended its debt agreements with Puritan Partners, extending the maturity date of two senior secured notes to December 11, 2024, and adjusting interest payment schedules.